Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
- Sponsor
- Getz Pharma
- Study ID
- NCT04976283
- Phase
- PHASE4
- Status
- Unknown
Conditions
- Diabetes Mellitus, Type 2
- NAFLD
- NASH - Nonalcoholic Steatohepatitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Accepted
Interventions
- Pioglitazone — DRUGPioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
- Empagliflozin — DRUGEmpagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
- Pioglitazone + Empagliflozin — DRUGPioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
Study Details
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin and/or DDP4 inhibitors.
Key Dates
- Start date
- Sep 15, 2021
- Status verified
- Mar 2022
- Primary completion
- May 15, 2023
- Completion
- Nov 15, 2023
Study Design
- Enrollment
- 123 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: PioglitazoneThe starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
- Active Comparator: EmpagliflozinThe starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
- Active Comparator: Pioglitazone + EmpagliflozinThe starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.
Primary Outcome Measure
Change in radiologic liver parameters [ Time Frame: 12 months ]
Central Contacts
- Azra Rizwan, FCPS+923212655271
Related Studies
- An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)Enrolling By Invitation · Novo Nordisk A/S · Morgantown, West Virginia
- Reversal of Lipid-Induced Insulin ResistanceRecruiting · Yale University · New Haven, Connecticut
- Bariatric Embolization of Arteries for the Treatment of Nonalcoholic SteatohepatitisNot Yet Recruiting · Keith Pereira, MD: · St Louis, Missouri
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas